Catalyst
Slingshot members are tracking this event:
KITE Posts Phase 2 Interim Analysis of ZUMA-1 Trial Evaluating KTE-C19 in Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) to be Presented at the American Society of Hematology (ASH) 58th Annual Meeting on December 6
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KITE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 06, 2016
Occurred Source:
https://ash.confex.com/ash/2016/webprogram/Paper98715.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Interim Analysis, Zuma-1, Kte-c19, Chemorefractory Aggressive, Non-hodgkin Lymphoma, Nhl, American Society Of Hematology
